All TKIs approved for CML therapy are recognized P-gp substrates, and high levels of ABCB1 expression (genes encoding P-gp) are associated with poorer long-term outcomes and advanced disease. The gene discussed is PGP; the disease is chronic myelogenous leukemia, BCR-ABL1 positive.